Latest Breaking News On - Clinical development plan - Page 1 : comparemela.com

Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2023 Financial Results and Announces Upcoming R&D Day

R&D Day on December 14 to provide clinical updates for BT8009, BT5528 and BT7480, and highlight broad capabilities of novel Bicycle® technology Alignment with FDA on expedited development and.

Bicycle Therapeutics Plc (BCYC) Reports Q3 Business Progress

Bicycle Therapeutics PLC (BCYC) Reports Q3 2023 Financial Results and Upcoming R&D Day

Company's cash and cash equivalents stand at $572.1 million as of September 30, 2023

Cardiff Oncology (CRDF) Announces Positive Clinical Data in Pancreatic Cancer and Small Cell Lung Cancer

Cardiff Oncology Announces Positive Clinical Data in Pancreatic Cancer and Small Cell Lung Cancer, including Single-Agent Activity from Onvansertib Monotherapy

Pancreatic Cancer Program - Pancreatic cancer Phase 2 trial of onvansertib + SoC in the second-line setting demonstrated greater efficacy vs. historical controls with ORR of 19% and mPFS of 5.0.